News archive
Showing 713 results
September 2011
-
Media Release
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
- ACZ885, which neutralizes key inflammatory driver interleukin-1 beta[1], provided significant symptom improvement vs. placebo in Phase III pivotal trial[2]- Systemic juvenile idiopathic arthritis… -
Media Release
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
August 2011
-
Media Release
FDA approves supplemental new drug application for Novartis therapy Gilenya™ to include data showing reduction in T1 lesions in MS, a marker of disease activity
- Gilenya-treated patients had fewer T1 gadolinium (Gd)- enhancing lesions versus those treated with interferon beta-1a IM at 12 months and placebo at 24 months - More than 11,000 people in U.S. have… -
Media Release
FDA approves supplemental new drug application for Novartis therapy Gilenya™ to include data showing reduction in T1 lesions in MS, a marker of disease activity
July 2011
-
Media Release
Novartis receives FDA approval for Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Arcapta is the only once-daily long-acting beta2-agonist (LABA) approved in US for maintenance treatment of airflow obstruction in patients with COPDClinical studies with Arcapta showed sustained… -
Media Release
Novartis receives FDA approval for Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
May 2011
-
Media Release
Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid
Two pivotal Phase III studies showed ACZ885 may meet significant unmet need for patients for whom many standard therapies are inadequate or inappropriate1,2Regulatory filings for the use of ACZ885 in… -
Media Release
Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid
-
Media Release
Novartis teams up with Phil Keoghan, host of “The Amazing Race,” to raise awareness for multiple sclerosis through inspirational national bike tour
New professional cycling team, called NOW and Novartis for MS, to compete nationally and ride tandem with MS patients in National MS Society’s bike rides Program kicks-off on the eve of World MS Day… -
Media Release
Novartis teams up with Phil Keoghan, host of “The Amazing Race,” to raise awareness for multiple sclerosis through inspirational national bike tour
-
Media Release
Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
- Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumors (NET) of pancreatic origin(1)- Afinitor represents a new approach to… -
Media Release
Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET